Co-Founder & CEO, Kyruus
Graham is the Co-Founder and the CEO of Kyruus. Prior to Kyruus, Graham was a Venture Executive at Highland Capital Partners where he co-founded Generation Health and served as the company’s Chief Medical Officer through its acquisition by CVS Caremark. He is also the Co-Founder of SynapDx, a molecular diagnostic company focused on developing a blood test to enable the earlier detection of Autism Spectrum Disorders. Graham completed his clinical training in internal medicine and cardiology at Beth Israel Deaconess Medical Center and Harvard Medical School, where he also served as Chief Medical Resident. Graham completed his BA and MD degrees at Brown University, and received his MBA from Harvard Business School.
Co-Founder & CSO, Kyruus
Julie is Co-Founder and Chief Strategy Officer at Kyruus, after serving for over 7 years as the company's founding Chief Product Officer. She drives the vision and strategy behind Kyruus' market-leading patient access products and go-to-market efforts, and oversees strategic partnerships and ecosystem development for the company. Julie previously played product leadership roles at Generation Health from inception through acquisition, and Knome, the world's first whole genome sequencing service for private individuals. Julie’s passion for search technologies and supply-demand matching businesses began as an early member of the software engineering team at Endeca Technologies. She studied computer science and pre-medicine at MIT, and obtained an MS and MBA from Harvard-MIT HST and MIT Sloan. Outside of Kyruus, Julie is a member of the Massachusetts Technology Leadership Council Board of Trustees, a Young Global Leader with the World Economic Forum, and a mom.
CEO, Partners in Health
Dr. Gary L. Gottlieb is the CEO of Partners In Health. From 2010 until February of 2015, he served as president and CEO of Partners HealthCare, the parent of the Brigham and Women’s and Massachusetts General Hospitals, operating the largest health care delivery organization in New England and among the nation’s largest nonprofit biomedical research and training enterprises. Dr. Gottlieb is a professor of psychiatry at Harvard Medical School and a member of the Institute of Medicine of the National Academies. He served as president of Brigham and Women’s/Faulkner Hospitals, as president of North Shore Medical Center, and as chairman of Partners Psychiatry. Prior to coming to Boston, Dr. Gottlieb spent 15 years in positions of increasing leadership in health care in Philadelphia. As a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania, he earned an M.B.A with distinction in health care administration from the Wharton Graduate School of Business Administration. Dr. Gottlieb is a member of the National Academy of Medicine and serves on the Board of the Federal Reserve Bank of Boston.
Managing Director, New Leaf Venture Partners
Vijay Lathi is a Managing Director focused on information convergence and diagnostics investments. Vijay joined Sprout in 1998, was promoted to Partner in 2003, and was one of the founders of New Leaf in 2005. Prior to focusing on information convergence, Vijay’s investment activity covered a range of healthcare technologies including HCIT, diagnostics and therapeutic platforms, and was the founding investor in both Ilypsa (sold to Amgen) and Relypsa (RLYP). Prior to joining Sprout, Vijay was an analyst in the Healthcare Venture Capital Group at Robertson Stephens & Co. and analyst at Cornerstone Research, a consulting firm focused on financial and economic analysis for business litigation. Vijay graduated from the Massachusetts Institute of Technology and Stanford University where he received his B.S. and M.S. in Chemical Engineering, with an emphasis on the application of engineering to life science technology.
Partner, Highland Capital Partners
Dan joined Highland in 1996 as a Partner to establish and build the firm’s internet investment practice. He is leading the firm’s expansion efforts into China. He continues to be an active investor focusing on technology and consumer investments with specific experience and interest in internet, digital marketing and media technologies. Dan has led the firm’s investments and served on the boards of a number of successful companies including: Amp Resources (acquired by Enel), Ask Jeeves (IPO), BeFree (IPO), Coremetrics (acquired by IBM), eToys (IPO), Fastclick (IPO, acquired by ValueClick), Gamesville (acq'd by Lycos), Lycos (IPO), MapQuest (IPO, acquired by AOL), N2 Broadband (acquired by TANDBERG), Navic Networks (acquired by Microsoft), NextCard (IPO), NYTimes Digital (acquired by New York Times), Qihoo 360 (IPO), Quote.com (acquired by Lycos), Raindance (IPO), RoweCom (IPO), StyleFeeder (acquired by Time, Inc.) and YogaWorks (acquired by Great Hill Partners). His current portfolio includes Beyond the Rack, CMI Marketing, HourlyNerd, Rent The Runway, ThredUp, and Yipit. Dan has been recognized by the prestigious Forbes Midas List as one of the top venture capitalists in the industry. Prior to joining Highland in 1996, Dan was a Partner at CMG@Ventures where he co-led the partnership's investment activities in early-stage internet companies. Dan earned a B.S., Computer Science and Marketing from Boston College and an M.B.A. from Harvard Business School.
Co-Founder, Lux Capital
Robert is Co-Founder of Lux Capital and focuses on ventures in healthcare. Robert graduated from the University of Virginia and has been a member of the Regional Selection Committee for UVA’s Jefferson Scholars Foundation. Robert was also a member of Motorola’s Research Visionary Board and an invited lecturer at the Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, Yale University, Georgetown, and the University of Virginia. He has been published in Journal of Biomedical Materials Research (Applied Biomaterials) and Nature Biotechnology. Robert was Founding CEO and is currently on the Board of Directors at Harvard Medical School spinout Genocea Biosciences (vaccine discovery). In 2009, Robert was nominated as Biotech CEO of the Year at the World Vaccine Congress. In 2010, Robert was selected as one of the “100 of the Most Inspiring People” by PharmaVoice Magazine. Robert is Co-Founder of Lux Research (emerging technology research), Founding CEO of Kala Pharmaceuticals (mucosal drug delivery), and has served as an Advisor to the Bill & Melinda Gates Foundation.
Bryan is a Partner at Venrock, joining the firm as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of health care investments. Bryan is currently Chairman of the Board of Directors of Achaogen, Castlight Health, and Ironwood Pharmaceuticals (NASDAQ: IRWD) and also serves on the Board of several other private companies, including Coderyte, Intarcia, Kyruus and Tandem Diagnostics. Past investments include athenahealth (NASDAQ: ATHN), Illumina (NASDAQ: ILMN), Sirna Therapeutics (acquired by Merck) and Xenoport (NASDAQ: XNPT). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has been the highest-ranking health care investor on Forbes’ Midas List since 2008. Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.
SVP & President, Cerner Health Ventures
Donald Trigg serves as Senior Vice President and President of Cerner Health Ventures. In his role, he focuses on analyzing early market segment and top health system opportunities and then working with Chief Executive Neal Patterson to advance a leadership position within them. Mr. Trigg rejoined Cerner in 2012 after the successful sale of Natural Language Processing (NLP) category leader CodeRyte to 3M’s healthcare division. During his time at the company, CodeRyte saw triple-digit bookings growth including the largest quarter in company history leading up to the acquisition in Q2 2012. Before joining CodeRyte, Trigg spent more than seven years at Cerner where he served in a variety of executive roles, including Managing Director of the company’s operations in the United Kingdom and Ireland in London, England; General Manager for the Kansas City, Missouri, geography; management of corporate communications and marketing operations worldwide; and creation of Cerner’s government practice. Beyond his decade in healthcare IT, Trigg also brings a broad public policy background to Cerner at a time of increased government presence in healthcare. He worked for President George W. Bush for almost four years, running the policy arm of the Department of Commerce for Secretary Donald Evans, working as a senior adviser in Austin, Texas, for the 2000 Bush for President campaign and serving on the 2001 Bush-Cheney transition team. Mr. Trigg also had a multi-year tenure on Capitol Hill, working in a series of senior policy positions in the U.S. Senate and the U.S. House. Mr. Trigg serves as a member of the advisory board of Western Governors University (WGU) and also sits on the Greater Kansas City board of the American Red Cross. Trigg graduated from St. Lawrence University in Canton, N.Y with a BA in Economics and U.S. History.
Chief Strategy Officer,
David Cannady is the chief strategy officer at Mercy Health, leading the ministry’s innovation and planning teams and coordinating implementation of the 2018-2020 Strategic Plan. David came to Mercy Health in May 2017 from Hospital Corporation of America (HCA) in Nashville, where he served as vice president of the Strategic Resource Group for a decade. HCA is one of the world’s largest healthcare delivery systems, with 171 hospitals and 118 freestanding surgery centers in 20 states and in the United Kingdom. During his tenure at HCA, David led a team that provided strategic planning and consulting for growth initiatives and hospital operations, managed reporting and progress on the strategic agenda, and helped develop strategies on service lines, clinically integrated networks and clinical co-management programs. Before joining HCA in 2002, David was a senior manager in the Health Care Consulting group at Cap Gemini Ernst & Young in Charlotte. A North Carolina native, he holds a bachelor’s degree in Public Health from the University of North Carolina and a master’s degree in Health Administration from Duke University.
Co-Founder & Managing Partner,
Leerink Transformation Partners
Todd is the co-founder and Managing Partner of Leerink Transformation Partners (LTP) with over 25 years of experience in the healthcare information technology and services industry. Toddhas led LTP’s investments in Health Catalyst, Outcome Health, Kyruus and PatientPing. Prior to forming LTP in 2016, he co-led healthcare investing at Sequoia Capital where he invested in and helped build defining healthcare companies like Health Catalyst, MedExpress (sold to UnitedHealth Group for $1.5B, a sale in which Todd was instrumental), Natera (IPO in 2015 - NASDAQ: NTRA) and ZirMed (sold recently to Bain Capital for $750 M after Todd’s introduction) from early growth stages onward. Prior to his time at Sequoia Capital, Todd led several business areas within Optum, a subsidiary of UnitedHealth Group, including strategy and M&A. Todd served as CEO of Optum’s Accountable Care Solutions business and helped with the formation and launch of Optum in 2011. Todd himself provided the seed capital for and was the Co-founder and CEO of Picis, Inc., the market leader in electronic medical records for the high acuity areas of the hospital (operating rooms, intensive care units, and emergency departments); in 2010, Picis was acquired by UnitedHealth Group. Before founding Picis, Todd started his operating career in healthcare by helping bootstrap and build Marquette Medical Systems and guiding it to leadership in cardiology diagnostics, patient monitoring and healthcare software solutions. He co-led the company’s IPO with the founder, and it was later acquired by GE for over $800 million. Todd is a board member of current portfolio partner companies Health Catalyst, PatientPing, Outcome Health, and Kyruus (observer). He is also a board member of Natera (NASDAQ: NTRA), ZirMed, StemCentrx, and SCIO Health Analytics. He is a former board member of PerfectServe, MedExpress, and AirStrip. Todd received a BA from Marquette University and completed Harvard Business School’s Program for Management Development (PMD). He sits on the executive committee of the InnerCity Scholarship Fund of Boston, as well as the Board of Overseers of Newton Wellesley Hospital. He is a member of the World Economic Forum’s Technology Council. Todd was a member of the US Sailing Team for three Olympiads, reaching a No. 2 worldwide ranking and winning several North American and European championships, two Bacardi Cups and a gold medal in the Pan American Games. Todd gave up grand prix sailing competition to focus on his other babies – the companies he founded and led and his family, wife Carme, daughters Chloe and Chantal. He has been trying to replace sailing with golf for ten years but admits that course records where he plays are in absolutely no danger of being broken when he’s playing.
General Counsel & Managing Director,
Gerson Lehrman Group
Laurence Herman serves as General Counsel and Managing Director at Gerson Lehrman Group (GLG). He oversees legal and compliance globally, and works closely with communications and business development. Earlier in his career, Laurence practiced law at Cahill Gordon & Reindel and was Senior Vice President, Operations, for Capital IQ, Inc. He worked in strategic development for Delphi Capital, working with the firm’s affiliated fund of funds and hedge funds, insurance companies and other investment projects.
Partner, F-Prime Capital
Jon Lim is a Partner who joined F-Prime Capital in 2011. Jon leads F-Prime’s investment efforts in Healthcare IT and Healthcare services, including F-Prime Capital’s investments in Liazon (acquired by Towers Watson), PatientPing, Kyruus, US HealthVest, Stride Health, TraceLink, VitalWare, WelbeHealth, Artemis Health, Protenus, Novaerus, and Procured Health. Most recently, Jon was a Principal at Polaris Partners, where he was part of the teams that led investments in several Software-as-a-Service companies (Phytel (acquired by IBM), Egnyte, Recurly, and KISSmetrics) as well as in Ocular Therapeutix (NASDAQ: OCUL) and SustainX. Jon began his investing career in 2002 as an Associate at Summit Partners, where his investments include MDVIP (acquired by Procter & Gamble) and Diagnostic Hybrids (acquired by Quidel). Jon also worked previously at Medtronic in their cardiac rhythm and disease management business. Jon holds an M.B.A. from Harvard Business School and an A.B. in East Asian Studies from Harvard College, where he graduated magna cum laude.
EVP, Chief Digital Officer, PSJH & Managing General Partner, Providence Ventures
Aaron Martin is responsible for digital, mobile and online marketing at PSJH, a not-for-profit health system that combines Providence Health & Services and St. Joseph Health, together comprising 106,000 caregivers across 50 hospitals and 829 clinics. He is also responsible for early stage/venture tech. and medical device investments for PV’s $150M fund, serving on the boards of portfolio companies AVIA and Kyruus. Prior to PSJH, Aaron worked for Amazon and McKinsey, and was an executive/founder of two tech companies. At Amazon, he led CreateSpace before running the Kindle North American Trade business.
SVP and Managing Director, McKesson Ventures
Tom leads the Venture efforts of McKesson (Fortune #5), which target and help scale emerging companies that are driving towards a stronger, more sustainable future for our health care industry. Specific focus for the fund is on technology-enabled services addressing the needs of pharma, pharmacy, providers and patients. Prior to rejoining McKesson, he spent more than a decade in health care venture capital, most recently leading strategic investing effort for Cambia Health and before that with Advanced Technology Ventures. Before his venture career Tom had significant operating experience in the health care industry including various strategy and commercial roles at leading companies such as McKesson, Genentech, FitLinxx, and The Wilkerson Group. Tom holds an M.B.A. from the Wharton School, and a B.A. from the University of Pennsylvania. He was also an All-American Rugby player.